Mutations in the BRAF gene have been reported in 7%–15% of all human cancers, with melanoma having one of the highest incidences (40%–70%). Other tumor types with a marked prevalence of BRAF V600 mutations include ovarian cancer (35%), colorectal cancer (12%), non-small cell lung cancer (NSCLC; up to 5%) and multiple myeloma (4%)¹.
The Idylla™ BRAF Mutation Assay detects BRAF mutations directly from FFPE tissue sections in 90 minutes with less than 2 minutes hands-on time.
The Idylla™ BRAF Mutation Assay, performed on the Biocartis Idylla™ system, is a sample-to-result real-time PCR assay for the qualitative detection of mutations in codon 600 of the BRAF oncogene. The Idylla™ BRAF Mutation Assay directly liberates DNA from FFPE tissue for subsequent real-time PCR amplification and detection. Fully automated software interpretation and reporting is also integrated, and provides a result in approx. 90 minutes.
YOU ARE ABOUT TO EXIT FOR ANOTHER BIOCARTIS COUNTRY OR REGION SPECIFIC WEBSITE
Please be aware that the website you have requested is intended for the residents of a particular country or countries, as noted on that site. As a result, the site may contain information on pharmaceuticals, medical devices and other products or uses of those products that are not approved in other countries or regions.
DO YOU WISH TO CONTINUE AND EXIT THIS SITE?
DISCLAIMER:
This information concerns a use that has not been approved or cleared by the Food and Drug Administration.
Biocartis is recruiting centers for a prospective biomarker study comparing turnaround times of standard of care methods and biomarker testing with Idylla™.
DISCLAIMER:
This presentation is intellectual property of the individual presenters. The opinions and conclusions expressed in these presentations are those of the individual presenters and do not necessarily reflect the views and opinions of Biocartis and/or its employees.
One of the biggest challenges oncology labs face with biomarker testing is the ability to obtain samples of sufficient size and quality. With the Idylla™ system only a minimal amount of sample is needed. For solid biopsies, just one slice of tissue is enough and our plasma-based assays require only 1 ml of plasma.
